Buscar
Alterity Therapeutics Ltd
ATHEAñadir a la lista de seguimiento
4.415USD
-0.070-1.56%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
67.16MCap. mercado
PérdidaP/E TTM
Más Datos de Alterity Therapeutics Ltd Compañía
Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase II clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.
Información de Alterity Therapeutics Ltd
Símbolo de cotizaciónATHE
Nombre de la empresaAlterity Therapeutics Ltd
Fecha de salida a bolsaMar 28, 2000
Director ejecutivoStamler (David A)
Número de empleados9
Tipo de seguridadDepository Receipt
Fin del año fiscalMar 28
DirecciónLevel 14, 350 Collins Street
CiudadMELBOURNE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísAustralia
Código postal3000
Teléfono61393494906
Sitio Webhttps://alteritytherapeutics.com/
Símbolo de cotizaciónATHE
Fecha de salida a bolsaMar 28, 2000
Director ejecutivoStamler (David A)
Ejecutivos de Alterity Therapeutics Ltd
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Peter Ashley Marks
Mr. Peter Ashley Marks
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Lawrence B. Gozlan
Mr. Lawrence B. Gozlan
Non-Executive Director
Non-Executive Director
--
--
Dr. David A. Stamler, M.D.
Dr. David A. Stamler, M.D.
Chief Executive Officer, Managing Director
Chief Executive Officer, Managing Director
--
--
Ms. Hannah Howlett
Ms. Hannah Howlett
Investor Relations
Investor Relations
--
--
Ms. Abby Macnish Niven
Ms. Abby Macnish Niven
Chief Financial Officer, Company Secretary
Chief Financial Officer, Company Secretary
--
--
Mr. Julian Barbaczy
Mr. Julian Barbaczy
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Peter Ashley Marks
Mr. Peter Ashley Marks
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Lawrence B. Gozlan
Mr. Lawrence B. Gozlan
Non-Executive Director
Non-Executive Director
--
--
Dr. David A. Stamler, M.D.
Dr. David A. Stamler, M.D.
Chief Executive Officer, Managing Director
Chief Executive Officer, Managing Director
--
--
Ms. Hannah Howlett
Ms. Hannah Howlett
Investor Relations
Investor Relations
--
--
Ms. Abby Macnish Niven
Ms. Abby Macnish Niven
Chief Financial Officer, Company Secretary
Chief Financial Officer, Company Secretary
--
--
Mr. Julian Barbaczy
Mr. Julian Barbaczy
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Alterity Therapeutics Ltd?
Los cinco principales accionistas de Alterity Therapeutics Ltd son: Mr. Peter Ashley Marks
¿Cuántas instituciones poseen acciones de Alterity Therapeutics Ltd (ATHE)?
A fecha de 2026Q1, 32 instituciones poseen acciones de Alterity Therapeutics Ltd, con un valor de mercado combinado de aproximadamente 327.31K, lo que representa el 1.81% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -185355.00.